Conheça novo colírio que melhora visão de perto sem óculos

[{"selector":"#anim-cb922332-0bff-4ba1-9ed7-6b18ba7ce698","keyframes":{"opacity":[0,1]},"delay":0,"duration":1000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-15555e2b-0d56-457a-8be5-9add964dd3f2","keyframes":{"opacity":[0,1]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-b34a569a-f009-4765-a2e0-69fb01df10b6","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-e95e9f2b-95b2-4585-8fe1-6f45b96ae4f3","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Freepik

[{"selector":"#anim-59f76bb2-aca0-41e3-9075-90726ff16f6f","keyframes":{"opacity":[0,1]},"delay":0,"duration":1500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f8a96ff8-9987-4a68-a822-9dcde10177bc","keyframes":{"opacity":[0,1]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-3b261556-3311-49b5-9f20-2096a9c46dde","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-76b89751-fae0-427d-9d36-7fd3ab909edc","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] O VIZZ é um colírio de uso diário à base de aceclidina (1,44%) aprovado pela FDA para tratar a presbiopia, condição que dificulta a visão de perto e afeta cerca de 1,8 bilhão de pessoas no mundo Reprodução/LENZ Therapeutics

[{"selector":"#anim-7b5ac11b-ae7e-4c55-9acc-9af81fa826ae","keyframes":{"opacity":[0,1]},"delay":0,"duration":1500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-266449a3-435e-49f7-8fac-79d9035f7fce","keyframes":{"opacity":[0,1]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-f097aff1-46df-4755-9454-c9eae1141f8e","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-c6bf9f24-c031-40fe-9d73-d26ca08b7193","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Desenvolvido pela LENZ Therapeutics , é o primeiro e único produto com essa substância autorizado para esse fim e tem previsão de chegar ao mercado americano no quarto trimestre de 2025 Unsplash

[{"selector":"#anim-5030c362-877f-47d1-b5e7-79ecc52ff134","keyframes":{"opacity":[0,1]},"delay":0,"duration":1500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-721bebf2-ba8c-4f10-a1b3-a71a9f2373ea","keyframes":{"opacity":[0,1]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-95190012-9b62-4a63-b9d5-ef5201f24be6","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-86926f64-8747-4568-bd3c-aee017fac1e0","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Seu mecanismo de ação contrai o músculo esfíncter da íris, aumentando a profundidade de foco e melhorando a visão de perto por até 10 horas sem causar desvio miópico Freepik

[{"selector":"#anim-db6ec3ca-d9ac-4327-8bfc-ddefdf7a6d7c","keyframes":{"opacity":[0,1]},"delay":0,"duration":1500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-bfd80a21-3bc3-4353-8c72-53b8d0c081b3","keyframes":{"opacity":[0,1]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-8b2c34e8-5374-4fd1-9fe6-ec34cade7c48","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-6b99fd70-00aa-4ba4-9f6f-fbc25ae36f08","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] A eficácia e segurança foram comprovadas em três estudos clínicos de fase 3, com mais de 600 participantes, mostrando resultados já a partir de 30 minutos após a aplicação Freepik

[{"selector":"#anim-ec9a84d1-2da8-4993-b87d-2873d91cf92e","keyframes":{"opacity":[0,1]},"delay":0,"duration":1500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-e9bf8203-fcc5-4481-a447-ed07a5ef53b1","keyframes":{"opacity":[0,1]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-53445d9d-2c4f-44de-892b-7a5627358134","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-45a47282-77e5-4760-9e2a-7d93c6a15a6c","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Os efeitos colaterais mais comuns foram leves e transitórios, como irritação ocular, visão turva e dor de cabeça Freepik

[{"selector":"#anim-399c689c-d299-4152-801e-6da4fd6e198f","keyframes":{"opacity":[0,1]},"delay":0,"duration":1500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-13bd0830-51af-4093-bc43-2f7501f77afb","keyframes":{"opacity":[0,1]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-8a47505c-edcc-43d8-883b-97883bd2395e","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-87aedd67-d1dc-44a2-a613-b05fdb756740","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] A novidade é vista como um marco para o tratamento da “vista cansada” e pode se tornar o novo padrão terapêutico entre oftalmologistas e optometristas Freepik

CNNBRASIL.COM.BR

[{"selector":"#anim-da2d9d46-8d20-482a-bf09-47842e8c588b","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-3fd88b95-10db-41a7-921b-6c0e6483a5f0","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-84ea012a-352f-4473-bebe-a45d5f260238","keyframes":{"opacity":[0,1]},"delay":0,"duration":1000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-258024b6-11ff-4030-8ce7-2bee215adab0","keyframes":{"transform":["translate3d(0px, 2132.63615%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":1000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-bc1e8222-42ea-4a59-93e6-01c49f93ef3b","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f133f294-7a0e-4c59-8175-b66a2f74ef6f","keyframes":{"transform":["translate3d(-117.84387%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-ee9ccc61-abdd-4a99-b078-20aa438b0b2b","keyframes":{"opacity":[0,1]},"delay":0,"duration":1000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-52278ac5-3bd1-44d0-ac47-de921ee28292","keyframes":{"transform":["translate3d(0px, 1223.93157%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":1000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] Freepik leia mais em